Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-negative, PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Fluorouracil, Oxaliplatin, Pembrolizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastro-osophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.